Skip to main content

Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.

Project description

Innovative bioengineered skin grafts for transplantation

Standard of care split-thickness skin autografting procedure for the treatment of skin wounds often leaves patients with scars. After transplantation, the lack of dermis in the transplant induces a quick body reaction to create scar tissue and activate contraction to reduce the wound area. Contraction is characterised by skin constriction that results in additional scarring and functional limitations. The Swiss company CUTISS invented and developed personalised, bioengineered human skin graft technology to produce large quantities originating from a stamp-sized skin biopsy of the patient. The dermo-epidermal structure of the novel autografts will result in minimal scarring after transplantation. The EU-funded denovoSkin project aims to finalise a development plan in regards to the clinical validation of the product and its industrialisation.

Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-1-2016-2017

Coordinator

CUTISS AG
Net EU contribution
€ 50 000,00
Address
Weinbergstrasse 35 Wyss Translational Center Zurich Denovos
8006 Zurich
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00